MAIA Biotechnology to Present at Two Investor Conferences in April 2024
Participants should refer to the final program agendas for up-to-date information.
- Participants should refer to the final program agendas for up-to-date information.
- MAIA’s lead candidate is THIO, a small molecule telomere-targeting anticancer agent that acts by producing direct telomeric DNA damage and inducing cancer-specific immune responses.
- Recent news from MAIA’s THIO-101 trial includes:
Early completion of enrollment; topline data expected in second half of 2024; ( press release, February 22, 2024 )
Strong response rate of 38% in third-line treatment efficacy data; ( press release, March 6, 2024 ). - Multiple paths to potential commercial approval of THIO under consideration; MAIA anticipates a final FDA decision on THIO in 2026; ( MAIA Shareholder Letter 2024 ).